Wed.Jun 14, 2023

article thumbnail

Bacterial infection may be ‘key event’ in common but mysterious endometriosis, study says

STAT

Endometriosis, a common gynecological condition, is one of health’s great mimickers. It can manifest as a variety of painful symptoms but evade detection on scans and examinations. And for the estimated 10% to 15% of women with endometriosis, it can take over a decade to get a diagnosis. Part of the lag is because researchers still don’t know exactly how endometriosis occurs, except that the flow of menstrual blood backward through the fallopian tubes plays a role in some cases.

280
280
article thumbnail

How steep is pharma’s patent cliff?

PharmaVoice

The big pharma patent cliff is almost here — and could change the face of the industry. Here’s a look at the key stats behind the coming wave of blockbuster losses.

130
130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Muzzled for years, vindicated MIT professor says fraud investigation into his lab did lasting damage

STAT

For three years, nine months, and one week, Ram Sasisekharan lived under a gag order. In 2019, some of the Massachusetts Institute of Technology professor’s peers publicly accused his lab of falsifying research, setting in motion a lengthy internal investigation that sidelined his work, decimated his team, and barred him from speaking out in his own defense.

260
260
article thumbnail

Creative Minds Make for Great Pharmacists

Pharmacy Is Right For Me

When it comes to pursuing a career in pharmacy, some may assume that it’s exclusively suited for those who have a strong scientific and mathematical background and analytical personality. However, this couldn’t be further from the truth. In fact, creative individuals can also find fulfilling careers in pharmacy, and here are a few reasons why.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

STAT+: Health insurance stocks tumble after UnitedHealth says Medicare enrollees are getting more care

STAT

A top executive at UnitedHealth Group said Tuesday that the health insurance and services conglomerate has noticed “a meaningfully higher number” of outpatient visits among Medicare patients in the second quarter of this year. The trend indicates a lot of older adults are getting care they had previously put off, which would eat into insurers’ earnings.

article thumbnail

Woman of the Week: Gamida Cell’s Abbey Jenkins

PharmaVoice

The first-time CEO discusses the lessons she has learned since taking the role last year and how she’s pivoting the company into a commercial entity.

130
130

More Trending

article thumbnail

Acadia gives once-rejected Prader-Willi drug a second chance

BioPharma Dive

The FDA last year turned back an approval request from the drug’s former developer, Levo Therapeutics. That biotech is now owned by Acadia, which will run a new study designed to boost its odds of success.

112
112
article thumbnail

Opinion: Listen: Physicians have a moral and professional obligation to get into ‘good trouble’

STAT

Just days after the end of Roe v. Wade, Caitlin Bernard, an OB-GYN in Indiana, told the Indianapolis Star a heartbreaking story: She had recently been asked to perform an abortion on a 10-year-old Ohio girl who had been raped. The end of Roe had ushered in a six-week abortion ban in Ohio, and the girl was just past that mark in her pregnancy, meaning she could not access care in her own state.

223
223
article thumbnail

340B program reaches $100 billion in sales, while patients are left behind

PhRMA

The 340B Drug Pricing Program has grown yet again , exceeding $100 billion in sales in 2022 when 340B-priced medicines are measured at wholesale acquisition cost. Recent data from IQVIA shows 340B grew 12.2% year-over-year in 2022, continuing a trend in which 340B sales have almost doubled since 2018, outpacing growth of the total U.S. drug market.

article thumbnail

STAT+: Pharmalittle: A not-so-new Biogen?; ALS Association and 15 chapters part ways over organizational clashes

STAT

Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? And what better way to make the time fly than to keep busy. So grab that cup of stimulation — our flavor today boasts the aroma of pumpkins — and get started. To help you along, we have assembled another menu of tidbits for you to peruse.

215
215
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

PharmaTimes Communications Awards 2023 - Everything you need to know!

Pharma Times

Find out more about the PharmaTimes Communications Awards 2023 – key dates, categories and which charity we have partnered with this year!

article thumbnail

STAT+: Federal advisory group rejects proposal to make medical device tracking easier

STAT

Every medical device has its own unique code, allowing manufacturers to keep track of their products once they enter the market. But while these codes are critical for recalling faulty devices or issuing updates, they rarely make their way into health records. For years, experts have argued for a simple fix: adding device identifiers to insurance claims forms, which doctors use to request reimbursement for medical services.

198
198
article thumbnail

Embracing the 60-Plus Economy

Pharmaceutical Commerce

In this latest Harvard Business School Healthcare Alumni Association Q&A, Susan Wilner Golden, DSC, lecturer at the Stanford Graduate School of Business, reveals an untapped $22 trillion global opportunity for all companies and others supporting healthy aging and longer life spans.

98
article thumbnail

Guidance to make repeat prescribing safer

The Pharmacist

The Royal Pharmaceutical Society (RPS) and the Royal College of GPs (RCGP) have been commissioned by NHS England to develop tools and guidance for use in primary care to improve repeat prescribing. The toolkit will aim to reduce overprescribing by improving the consistency of repeat prescribing processes and by providing training resources for clinicians.

94
article thumbnail

US FDA grants fast track status for CellCentric’s inobrodib

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted fast track designation for CellCentric’s inobrodib (CCS1477) to treat relapsed or refractory multiple myeloma patients. Inobrodib is an oral first-in-class cancer drug, indicated for patients who have previously received four or more lines of therapy, including an anti-CD38 monoclonal antibody, an immunomodulatory agent and a proteasome inhibitor.

97
article thumbnail

No new funding for ARRS pay increases

The Pharmacist

Primary care networks (PCNs) will be able to uplift the salaries of pharmacists recruited under the additional roles reimbursement scheme (ARRS) in line with the government’s latest NHS pay deal, but have not been given a funding increase to do so. The move – confirmed by NHS England (NHSE) – means PCNs will be able […] The post No new funding for ARRS pay increases appeared first on The Pharmacist.

90
article thumbnail

ASCO 2023 – Corina Dutcus

pharmaphorum

At ASCO 2023 last week in Chicago, Editor in Chief Jonah Comstock caught up with Dr Corina Dutcus, SVP clinical development at Eisai US, to talk about the CLEAR trial, one of Eisai’s major abstracts being presented at the show.

92
article thumbnail

Pharma1 | Mastering the First Impression

PioneerRx

Pharma1 Pharmacy & Wellness Center in McKinney, TX is not your average pharmacy. As soon as you step through the door, you get a relaxed, spa-like feel from.

98
article thumbnail

Owlstone Medical delivers breath biopsy test data

Pharma Times

Preliminary data has shown excellent safety, while also demonstrating proof of mechanism - News - PharmaTimes

109
109
article thumbnail

Improving patient experience doesn't come at cost of site burden Mural Health says

Outsourcing Pharma

Mural Health is on a mission to make it as easy as possible for people to take part in clinical trials, the company will be heading to DIA Global in Boston where they hope to glean a meaningful understanding of the current landscape and hot topics.

80
article thumbnail

Gilead to reveal pivotal liver disease research

Pharma Times

Gilead will present real-world data on its efforts to advance WHO’s aim of eliminating viral hepatitis - News - PharmaTimes

88
article thumbnail

Advanced Clinical to host event looking at increasing clinical research talent at DIA 2023

Outsourcing Pharma

In a bid to address the high demand for clinical research talent, Advanced Clinical is hosting an innovation theater at DIA Global in Bostonâs Convention and Exhibition Center.

79
article thumbnail

Samsung Biologics partners with Pfizer for manufacturing of biosimilars portfolio

Express Pharma

Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio Samsung Biologics and Pfizer announced a strategic partnership for the long-term commercial manufacturing of Pfizer’s multi-product portfolio. Samsung Biologics and Pfizer entered into an initial manufacturing agreement in March 2023 for a Pfizer product.

article thumbnail

Phastar to 'demystify statistical concepts' during DIA and demonstrate the value of data science

Outsourcing Pharma

Phastar is a specialist biometrics contract research organization offering statistical consulting, clinical trial reporting, data management and data science services and will be providing a presentation and running a workshop to give delegates working in any study function a deeper understanding of the interpretation of common statistical terminolgy.

77
article thumbnail

Langham Logistics Enhances Phoenix GMP Warehouse

Pharmaceutical Commerce

Changes to 3PL’s facility feature newly-converted controlled room temperature pallets.

98
article thumbnail

CluePoints - paving the path for risk-based quality management and sharing insight at DIA Global

Outsourcing Pharma

CluePoints is continuing to invest in artificial intelligence (AI) and machine learning (ML) they say they want to help clients 'extract every drop of potential from the RBQM-driven interrogation of their own datasets'. It says it recognizes the importance of educating the industry on the value of this approach.

76
article thumbnail

In-ear wearable start-up STAT has long COVID in its sights

pharmaphorum

In-ear wearable start-up STAT has long COVID in its sights Phil.

108
108
article thumbnail

Phastar's DIA 2023 Global Inspire Award for Community Engagement winner to present at this year's conference

Outsourcing Pharma

A statistics manager at specialist biometrics contract research organization (CRO) Phastar, has been chosen to receive the DIA 2023 Global Inspire Award for Community Engagement.

66
article thumbnail

Astellas delves deeper into protein degrading drugs with Cullgen deal

BioPharma Dive

The alliance is Astellas’ second recent partnership involving protein degraders, an emerging area of drug research the company has made a focus in recent years.

65
article thumbnail

A World Without Disease – AstraZeneca and the Health Works Initiative

pharmaphorum

A World Without Disease – AstraZeneca and the Health Works Initiative Mike.

96
article thumbnail

Study of 2seventy Bio’s AML cell therapy paused after patient death

BioPharma Dive

Researchers at study sponsor Seattle Children's have halted testing as they investigate the death and its potential link to the CAR-T treatment.

68
article thumbnail

Episode 826: Just How Bad Are Probiotics in the ICU?

Pharmacy Joe

In this episode, I’ll discuss probiotic-associated central venous catheter bloodstream infections in the ICU. Episode 826: Just How Bad Are Probiotics in the ICU? Subscribe on iTunes , Android , or Stitcher While probiotics are typically seen as a harmless intervention that may have benefits related to antibiotic-associated diarrhea, bloodstream infections caused by organisms contained within probiotics have been reported in ICU patients.

article thumbnail

Scientists discover small RNA that regulates bacterial infection

World Pharma News

People with weakened immune systems are at constant risk of infection. Pseudomonas aeruginosa, a common environmental bacterium, can colonize different body parts, such as the lungs, leading to persistent, chronic infections that can last a lifetime - a common occurrence in people with cystic fibrosis. But the bacteria can sometimes change their behavior and enter the bloodstream, causing chronic localized infections to become acute and potentially fatal.

article thumbnail

Seagen says Adcetris/Opdivo combo aces lymphoma trial

pharmaphorum

Seagen says Adcetris/Opdivo combo aces lymphoma trial Phil.

96
article thumbnail

mdgroup aiming for a 'person-first' rather than 'technology first' clinical research environment

Outsourcing Pharma

The message mdgroup, an organization devoted to creating 'remarkable patient experiences through solutions for clinical trial recruitment, engagement, retention, and outcomes', is that its focus is on people not technology.

52